Showing results (171-180 of 396) with videos related to

Sort By:
Pageof 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 28, 2017
Feasibility of Ultra-High-Throughput Functional Screening of Melanoma Biopsies for Discovery of Novel Cancer Drug CombinationsAdam A Friedman, Yun Xia, Lorenzo Trippa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2011
Large-scale analysis of KIT aberrations in Chinese patients with melanomaYan Kong, Lu Si, Yanyan Zhu, et al.
Oncotarget|April 16, 2014
PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutationFrancesco Sabbatino, Yangyang Wang, Xinhui Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 14, 2015
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805Naomi B Haas, Judith Manola, Bonnie Ky, et al.
European Journal of Cancer (Oxford, England : 1990)|May 19, 2015
Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progressionIgor Puzanov, Ravi K Amaravadi, Grant A McArthur, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain MetastasesRavi K Amaravadi, Lynn M Schuchter, David F McDermott, et al.
Biorxiv : the Preprint Server for Biology|May 25, 2026
Genomic, Clinical, and Spatial Predictors of Durable Response to BRAF/MEK Inhibition in <i>BRAF</i> -Mutant MelanomaYingxiao Shi, Alexander Savchenko, Jan Christoph Brase, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2020
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinomaEileen M O'Reilly, Diletta Barone, Devalingam Mahalingam, et al.
Science Advances|June 24, 2021
Rejection of benign melanocytic nevi by nevus-resident CD4<sup>+</sup> T cellsErik B Schiferle, Se Yun Cheon, Seokjin Ham, et al.
Nature Communications|October 16, 2021
Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanomaKuang Du, Shiyou Wei, Zhi Wei, et al.
Pageof 40